Difference between revisions of "Bone sarcoma"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "==[https://www.nccn.org/ NCCN]==" to "==NCCN==") |
Warner-admin (talk | contribs) m (Text replacement - "http://www.esmo.org/" to "https://www.esmo.org/") |
||
| Line 17: | Line 17: | ||
=Guidelines= | =Guidelines= | ||
'''Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.''' | '''Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.''' | ||
| − | ==[ | + | ==[https://www.esmo.org/ ESMO]/EURACAN/GENTURIS/PaedCan== |
*'''2021:''' Strauss et al. [https://doi.org/10.1016/j.annonc.2021.08.1995 Bone sarcomas: ESMO–EURACAN–GENTURIS–ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up] [https://pubmed.ncbi.nlm.nih.gov/34500044/ PubMed] | *'''2021:''' Strauss et al. [https://doi.org/10.1016/j.annonc.2021.08.1995 Bone sarcomas: ESMO–EURACAN–GENTURIS–ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up] [https://pubmed.ncbi.nlm.nih.gov/34500044/ PubMed] | ||
**'''2018:''' Casali et al. [https://doi.org/10.1093/annonc/mdy310 Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up] [https://pubmed.ncbi.nlm.nih.gov/30285218/ PubMed] | **'''2018:''' Casali et al. [https://doi.org/10.1093/annonc/mdy310 Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up] [https://pubmed.ncbi.nlm.nih.gov/30285218/ PubMed] | ||
Latest revision as of 17:51, 23 June 2024
| Section editor | |
|---|---|
 |
Elizabeth J. Davis, MD Vanderbilt University Nashville, TN, USA |
0 regimens on this page
0 variants on this page
|
Note: this page is for subtype-nonspecific bone sarcoma regimens, and some subtypes with very few subtype-specific regimens. Please see the category page for links to other sarcoma types or use one of these links:
Guidelines
Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.
ESMO/EURACAN/GENTURIS/PaedCan
- 2021: Strauss et al. Bone sarcomas: ESMO–EURACAN–GENTURIS–ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up PubMed
- 2018: Casali et al. Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up PubMed
- 2014: Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up PubMed
- 2012: Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up PubMed
- 2010: Hogendoorn et al. Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up PubMed
NCCN
- NCCN Guidelines - Bone Cancer
- 2013: Biermann et al. Bone cancer. PubMed
- 2010: Biermann et al. Bone cancer. PubMed
- 2007: Biermann et al. Bone cancer. PubMed
- 2005: Biermann et al. Bone cancer clinical practice guidelines. PubMed
Chondrosarcoma, all lines of therapy
- No standard chemotherapy for grades 1 to 3 conventional chondrosarcoma
- Mesenchymal chondrosarcoma has been treated with Ewing's sarcoma regimens
- Dedifferentiated chondrosarcoma has been treated with osteosarcoma regimens
Undifferentiated pleomorphic sarcoma (UPS) of bone, all lines of therapy
- Undifferentiated pleomorphic sarcoma (UPS) of bone has been treated with osteosarcoma regimens